Search Results - "Elsayed, Mei"

Therapeutic Sequencing in ALK + NSCLC by Elsayed, Mei, Christopoulos, Petros

“…Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK NSCLC) is a model disease for the use of targeted pharmaceuticals in thoracic oncology…”
Get full text

EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non‐small cell lung cancer by Christopoulos, Petros, Endris, Volker, Bozorgmehr, Farastuk, Elsayed, Mei, Kirchner, Martina, Ristau, Jonas, Buchhalter, Ivo, Penzel, Roland, Herth, Felix J., Heussel, Claus P., Eichhorn, Martin, Muley, Thomas, Meister, Michael, Fischer, Jürgen R., Rieken, Stefan, Warth, Arne, Bischoff, Helge, Schirmacher, Peter, Stenzinger, Albrecht, Thomas, Michael

“…In order to identify anaplastic lymphoma kinase‐driven non‐small cell lung cancer (ALK+ NSCLC) patients with a worse outcome, who might require alternative…”
Get full text

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer by Elsayed, Mei, Bozorgmehr, Farastuk, Kazdal, Daniel, Volckmar, Anna-Lena, Sültmann, Holger, Fischer, Jürgen R, Kriegsmann, Mark, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros

“…Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK NSCLC) is a model disease for use of targeted therapies (TKI), which are administered…”
Get full text